Trial Profile
Efficacy of vorinostat on overall survival in patients with acute myeloid leukemia (AML) with FLT3 ITD mutations.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jul 2015
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 13 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.